News

The Latest in DMT Research: Leading Companies and Key Studies

Truffle Report put together this roundup of the top corporate and scientific developments involving the psychoactive compound N, N-dimethyltryptamine (DMT). Small Pharma is featured alongside a number of leading companies and key studies covering the latest in DMT.

In addition to Small Pharma’s research trials into DMT-assisted therapy for major depression disorder, the report covers other key studies of DMT including:


  • Akome Biotech: Targeting Stroke and Parkinson’s Disease with DMT-Based Drug Formulas
  • Algernon Pharmaceuticals: DMT for Stroke Patients
  • Entheon Biomedical: DMT and DMT-Analogs to Treat Nicotine Addiction
  • MindMed: Investigating the Safety and Efficacy of Intravenous Administration of DMT
  • PharmaDrug: DMT to Prevent Vision Loss
  • Psilera Bioscience: Developing Non-Hallucinogenic DMT-Derivatives
  • Sairiyo Therapeutics: Exploring DMT’s Role in Improving Organ Transplant Safety
  • Vocan Biotechnologies: Biosynthesizing DMT at Scale
 

READ THE FULL TRUFFLE REPORT ARTICLE HERE

About Small Pharma

We’re a mental health drug development company that’s accelerating the development of fast acting antidepressant treatments using DMT based therapies. We’re dedicated to making a difference.

With a focus on innovative approaches and committed to challenging the status quo, we’re targeting the root causes of depression and hoping to unlock the minds of millions.

Get Small Pharma updates

    Investor Deck

    Follow us: